Literature DB >> 16870797

Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.

Santosh Katiyar1, Michael Pfaller, Thomas Edlind.   

Abstract

A recognized hotspot for mutations conferring reduced echinocandin susceptibility (RES) is residue S645 of Candida albicans Gsc1(Fks1). We report that the mutation F641Y is associated with RES in a C. albicans isolate. The analogous Fks2 residue is mutated F to V in a Candida glabrata RES isolate; the introduction of this mutation into susceptible C. glabrata confirmed its role in RES. Y641-equivalent Fks residues were identified in intrinsically RES Fusarium species and Candida guilliermondii.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16870797      PMCID： PMC1538661          DOI： 10.1128/AAC.00349-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

Review 1.  Glucan synthase inhibitors as antifungal agents.

Authors:  M B Kurtz; J H Rex
Journal:  Adv Protein Chem       Date:  2001

2.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

Review 3.  Echinocandin antifungal drugs.

Authors:  David W Denning
Journal:  Lancet       Date:  2003-10-04       Impact factor: 79.321

4.  Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation.

Authors:  W Lamar Smith; Thomas D Edlind
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

5.  Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies.

Authors:  M B Kurtz; G Abruzzo; A Flattery; K Bartizal; J A Marrinan; W Li; J Milligan; K Nollstadt; C M Douglas
Journal:  Infect Immun       Date:  1996-08       Impact factor: 3.441

6.  Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New York City (Candida Susceptibility Trends Study, 1998 to 1999).

Authors:  Amar Safdar; Vishnu Chaturvedi; Brian S Koll; Davise H Larone; David S Perlin; Donald Armstrong
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Genome evolution in yeasts.

Authors:  Bernard Dujon; David Sherman; Gilles Fischer; Pascal Durrens; Serge Casaregola; Ingrid Lafontaine; Jacky De Montigny; Christian Marck; Cécile Neuvéglise; Emmanuel Talla; Nicolas Goffard; Lionel Frangeul; Michel Aigle; Véronique Anthouard; Anna Babour; Valérie Barbe; Stéphanie Barnay; Sylvie Blanchin; Jean-Marie Beckerich; Emmanuelle Beyne; Claudine Bleykasten; Anita Boisramé; Jeanne Boyer; Laurence Cattolico; Fabrice Confanioleri; Antoine De Daruvar; Laurence Despons; Emmanuelle Fabre; Cécile Fairhead; Hélène Ferry-Dumazet; Alexis Groppi; Florence Hantraye; Christophe Hennequin; Nicolas Jauniaux; Philippe Joyet; Rym Kachouri; Alix Kerrest; Romain Koszul; Marc Lemaire; Isabelle Lesur; Laurence Ma; Héloïse Muller; Jean-Marc Nicaud; Macha Nikolski; Sophie Oztas; Odile Ozier-Kalogeropoulos; Stefan Pellenz; Serge Potier; Guy-Franck Richard; Marie-Laure Straub; Audrey Suleau; Dominique Swennen; Fredj Tekaia; Micheline Wésolowski-Louvel; Eric Westhof; Bénédicte Wirth; Maria Zeniou-Meyer; Ivan Zivanovic; Monique Bolotin-Fukuhara; Agnès Thierry; Christiane Bouchier; Bernard Caudron; Claude Scarpelli; Claude Gaillardin; Jean Weissenbach; Patrick Wincker; Jean-Luc Souciet
Journal:  Nature       Date:  2004-07-01       Impact factor: 49.962

8.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.

Authors:  Michel Laverdière; Richard G Lalonde; Jean-Guy Baril; Donald C Sheppard; Steven Park; David S Perlin
Journal:  J Antimicrob Chemother       Date:  2006-02-07       Impact factor: 5.790

9.  FKS1 mutations responsible for selective resistance of Saccharomyces cerevisiae to the novel 1,3-beta-glucan synthase inhibitor arborcandin C.

Authors:  Takao Ohyama; Shunichi Miyakoshi; Fujio Isono
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

10.  Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.

Authors:  Steve Hernandez; José L López-Ribot; Laura K Najvar; Dora I McCarthy; Rosie Bocanegra; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191
View more
  88 in total

1.  Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.

Authors:  Olivier Lortholary; Marie Desnos-Ollivier; Karine Sitbon; Arnaud Fontanet; Stéphane Bretagne; Françoise Dromer
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Quick Detection of FKS1 Mutations Responsible for Clinical Echinocandin Resistance in Candida albicans.

Authors:  Catiana Dudiuk; Soledad Gamarra; Cristina Jimenez-Ortigosa; Florencia Leonardelli; Daiana Macedo; David S Perlin; Guillermo Garcia-Effron
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

3.  Mitochondrial sorting and assembly machinery subunit Sam37 in Candida albicans: insight into the roles of mitochondria in fitness, cell wall integrity, and virulence.

Authors:  Yue Qu; Branka Jelicic; Filomena Pettolino; Andrew Perry; Tricia L Lo; Victoria L Hewitt; Farkad Bantun; Traude H Beilharz; Anton Y Peleg; Trevor Lithgow; Julianne T Djordjevic; Ana Traven
Journal:  Eukaryot Cell       Date:  2012-01-27

4.  Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.

Authors:  Jennifer Nielsen Kahn; Guillermo Garcia-Effron; Ming-Jo Hsu; Steven Park; Kieren A Marr; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

Review 5.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

6.  Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.

Authors:  John D Cleary; Guillermo Garcia-Effron; Stanley W Chapman; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

Review 7.  Resistance to echinocandin-class antifungal drugs.

Authors:  David S Perlin
Journal:  Drug Resist Updat       Date:  2007-06-13       Impact factor: 18.500

Review 8.  Interplay between Candida albicans and the antimicrobial peptide armory.

Authors:  Marc Swidergall; Joachim F Ernst
Journal:  Eukaryot Cell       Date:  2014-06-20

9.  Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

10.  CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction.

Authors:  Kelley R Healey; Santosh K Katiyar; Shriya Raj; Thomas D Edlind
Journal:  Mol Microbiol       Date:  2012-08-22       Impact factor: 3.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.